Cetuximab is a chimeric immunoglobulin G1 (IgG1) which targets EGFR, a member of receptor tyrosine kinases (TK) highly expressed in several types of cancers, including breast, lung, colorectal and head and neck cancers. Here, EGFR is linked to cancer.